Sheng Yajun, Zhang Chen, Qiu Xingye, Zheng Wei, Ruan Jishou, Shao Yiming
College of Mathematical Sciences and LPMC, Nankai University, Tianjin, PRC 300071, China.
Curr Comput Aided Drug Des. 2013 Dec;9(4):547-55. doi: 10.2174/15734099113099990025.
The RNA polymerase of Influenza A virus (IAV), which is comprised of three units PA, PB1 and PB2, is involved in transcription and replication of the influenza virus. In order to develop effective treatment for IAV, researchers have focused on designing drugs targeting IAV polymerase. Currently, crystal structures of the IAV polymerase PA-PB1, PB1-PB2 complexes and the PA subunit have been obtained by several groups, providing useful information regarding potential binding sites in drug design. However, to gain full understanding of the molecular mechanism of IAV polymerase in viral transcription and replication, thereby aiding drug development, a complete atomistic structure of the RNA polymerase is required. In this paper, we employed computer-aided drug design tools to describe the complete structure of the RNA polymerase and proposed a putative mechanism. We predict that the combination of Vancomycin and Oseltamivir will be an effective drug to universally treat IAVs with no resultant drug resistance if this putative mechanism is true.
甲型流感病毒(IAV)的RNA聚合酶由PA、PB1和PB2三个亚基组成,参与流感病毒的转录和复制。为了开发针对IAV的有效治疗方法,研究人员专注于设计靶向IAV聚合酶的药物。目前,多个研究小组已获得了IAV聚合酶PA-PB1、PB1-PB2复合物以及PA亚基的晶体结构,为药物设计中的潜在结合位点提供了有用信息。然而,为了全面了解IAV聚合酶在病毒转录和复制中的分子机制,从而助力药物开发,需要RNA聚合酶的完整原子结构。在本文中,我们使用计算机辅助药物设计工具来描述RNA聚合酶的完整结构,并提出了一种假定机制。我们预测,如果这种假定机制正确,万古霉素和奥司他韦的组合将是一种能普遍治疗IAV且不会产生耐药性的有效药物。